Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

A Randomized Prospective Evaluation of Four Injectable Neuromodulators in the Glabella Area

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05167864

Acronym

JBDX

Enrollment

143

Registered

2021-12-22

Start date

2022-03-04

Completion date

2023-06-30

Last updated

2025-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cosmetic Techniques

Keywords

minimally invasive procedures, neurotoxins, cosmetic, Botox, eyebrow area, glabella, Dysport, Jeuveau, Xeomin, forehead, cosmetic injections, facial rejuvenation, wrinkle reduction

Brief summary

The purpose of the study is to use 3D imaging to evaluate the effects of four FDA approved neuromodulators on facial lines, wrinkles and animation. Participation is available to women who have never had a cosmetic procedure above the malar region nor a treatment with a neuromodulator within 12 months. All subjects will undergo 3D imaging using the VECTRA M3 (Canfield Scientific, Inc, Fairfield, NJ) prior to treatment with a neuromodulator in order to determine their baseline dimensions. Imaging will be repeated post injection to determine change over time.

Detailed description

This study is a randomized controlled trial in which patients will be randomly assigned into one of four groups: those receiving onabotulinumtoxinA (Botox, Allergan, Irvine, California), abobotulinumtoxinA (Dysport, Ispen Biopharmacueticals Inc.Cambridge, MA), incobotulinumtoxinA (Xeomin, Raleigh, NC) or prabotulinumtoxinA (Jeuveau, Evolus, Newport Beach, California). Each patient will receive FDA approved dosages in which they are assigned in to treat rhytids within the glabella, as per FDA approved indications. All injections will be performed by a blinded single trained physician according to a preset injection plan per FDA approved administration guidelines. Prior to injection patients will be imaged with 3-dimensional photogrammetry. All pre-procedure images will be evaluated for absolute strain performing two types of facial animation: 1) relaxed, and 2) frowning. Subjects will return Day 3, 30, 90, and 180, post intervention for re-imaging with the same expressions. Strain will be calculated using the same metrics.

Interventions

DRUGOnabotulinumtoxina for Injection

cosmetic injection into the glabella area (eyebrow area)

DRUGAbobotulinumtoxina for Injection

cosmetic injection into the glabella area (eyebrow area)

DRUGIncobotulinumtoxinA for Injection

cosmetic injection into the glabella area (eyebrow area)

DRUGPrabotulinumtoxinA for Injection

cosmetic injection into the glabella area (eyebrow area)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Caregiver)

Masking description

blinding of participant and provider administering the treatment

Intervention model description

randomized controlled trial in which patients will be randomly assigned into one of four groups

Eligibility

Sex/Gender

FEMALE

Age

30 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Female * 30-65 years of age * Interested in glabellar injections to reduce rhytids and facial strain * Participants must sign the informed consent form

Exclusion criteria

* Females under 30 or above 65 years of age * Males * Those who have received glabellar injections for rhytids \<12 months * Underwent cosmetic surgical procedure above the malar region * Those with a condition that affects facial expression, such as prior stroke

Design outcomes

Primary

Measure	Time frame	Description
the Change in Dynamic Strain in the Glabella Area After Injection Over Time	day 3, day 30, day 90, day 180	The change in dynamic strain of the glabella area after injection using 3D facial imaging measurements over time At each visit two images were captured, one neutral and one dynamic. The neutral face was relaxed and served as a reference while the dynamic face was the subject's expression when asked to furrow their glabella by frowning (compressed face). A decrease in strain indicates reduced compression, as there is a smaller difference between the neutral face and the dynamic, or compressed, face.

Secondary

Measure	Time frame	Description
Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	baseline, day 3, day 30, day 90, day 180	Correlation of patient reported satisfaction (FACE-Q) to the degree of dynamic strain overtime. Correlation is determined at each time point post intervention Day 3, Day 30, Day 90 and Day 180.

Countries

United States

Participant flow

Participants by arm

Arm	Count
OnabotulinumtoxinA Botox Onabotulinumtoxina for Injection: cosmetic injection into the glabella area (eyebrow area)	35
AbobotulinumtoxinA Dysport Abobotulinumtoxina for Injection: cosmetic injection into the glabella area (eyebrow area)	36
IncobotulinumtoxinA Xeomin IncobotulinumtoxinA for Injection: cosmetic injection into the glabella area (eyebrow area)	36
PrabotulinumtoxinA Jeuveau PrabotulinumtoxinA for Injection: cosmetic injection into the glabella area (eyebrow area)	36
Total	143

Withdrawals & dropouts

Period	Reason	FG000	FG001	FG002	FG003
Overall Study	Lost to Follow-up	7	6	7	9

Baseline characteristics

Characteristic	OnabotulinumtoxinA	AbobotulinumtoxinA	IncobotulinumtoxinA	PrabotulinumtoxinA	Total
Age, Continuous	45.5 years STANDARD_DEVIATION 10.3	44.2 years STANDARD_DEVIATION 9.5	42.5 years STANDARD_DEVIATION 10.6	41.9 years STANDARD_DEVIATION 8.9	43.5 years STANDARD_DEVIATION 9.8
Race/Ethnicity, Customized African American/Black	2 Participants	3 Participants	2 Participants	0 Participants	7 Participants
Race/Ethnicity, Customized Asian	1 Participants	3 Participants	0 Participants	2 Participants	6 Participants
Race/Ethnicity, Customized Declined to Answer	3 Participants	0 Participants	1 Participants	1 Participants	5 Participants
Race/Ethnicity, Customized White/Caucasian	29 Participants	30 Participants	33 Participants	33 Participants	125 Participants
Sex: Female, Male Female	35 Participants	36 Participants	36 Participants	36 Participants	143 Participants
Sex: Female, Male Male	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk
deaths Total, all-cause mortality	0 / 35	0 / 36	0 / 36	0 / 36
other Total, other adverse events	0 / 35	0 / 36	0 / 36	0 / 36
serious Total, serious adverse events	0 / 35	0 / 36	0 / 36	0 / 36

Outcome results

Primary

the Change in Dynamic Strain in the Glabella Area After Injection Over Time

The change in dynamic strain of the glabella area after injection using 3D facial imaging measurements over time At each visit two images were captured, one neutral and one dynamic. The neutral face was relaxed and served as a reference while the dynamic face was the subject's expression when asked to furrow their glabella by frowning (compressed face). A decrease in strain indicates reduced compression, as there is a smaller difference between the neutral face and the dynamic, or compressed, face.

Time frame: day 3, day 30, day 90, day 180

Population: the change in dynamic strain is determined by measurements changes from two 3D images, if the images were not captured or the images were deemed unanalyzable then the population analyzed varies from the participant count.

Arm	Measure	Group	Value (MEAN)	Dispersion
OnabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 3	6.4 percent difference of neutral+dyanamic	Standard Deviation 5
OnabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 30	8.6 percent difference of neutral+dyanamic	Standard Deviation 5.4
OnabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 90	4.5 percent difference of neutral+dyanamic	Standard Deviation 4.6
OnabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 180	0.18 percent difference of neutral+dyanamic	Standard Deviation 4.1
AbobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 30	10.6 percent difference of neutral+dyanamic	Standard Deviation 6.2
AbobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 90	5.7 percent difference of neutral+dyanamic	Standard Deviation 5.2
AbobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 180	2.3 percent difference of neutral+dyanamic	Standard Deviation 5.6
AbobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 3	10.9 percent difference of neutral+dyanamic	Standard Deviation 5.2
IncobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 90	3.6 percent difference of neutral+dyanamic	Standard Deviation 5.3
IncobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 30	9.2 percent difference of neutral+dyanamic	Standard Deviation 5.7
IncobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 180	2.6 percent difference of neutral+dyanamic	Standard Deviation 4.7
IncobotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 3	6.6 percent difference of neutral+dyanamic	Standard Deviation 5.6
PrabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 180	3.1 percent difference of neutral+dyanamic	Standard Deviation 4.4
PrabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 30	10.4 percent difference of neutral+dyanamic	Standard Deviation 4.3
PrabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 3	8.9 percent difference of neutral+dyanamic	Standard Deviation 4.6
PrabotulinumtoxinA	the Change in Dynamic Strain in the Glabella Area After Injection Over Time	Day 90	5.2 percent difference of neutral+dyanamic	Standard Deviation 3.7

Secondary

Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime

Correlation of patient reported satisfaction (FACE-Q) to the degree of dynamic strain overtime. Correlation is determined at each time point post intervention Day 3, Day 30, Day 90 and Day 180.

Time frame: baseline, day 3, day 30, day 90, day 180

Population: population of who answered the FACE-Q can be analyzed

Arm	Measure	Group	Value (MEAN)	Dispersion
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 90	-0.028 correlation coefficient	Standard Error 0.087
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 3	-0.015 correlation coefficient	Standard Error 0.031
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 3	-0.0870 correlation coefficient	Standard Error 0.057
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 180	-0.086 correlation coefficient	Standard Error 0.048
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 180	-0.053 correlation coefficient	Standard Error 0.081
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 180	0.024 correlation coefficient	Standard Error 0.041
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 30	0.033 correlation coefficient	Standard Error 0.492
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 3	-0.059 correlation coefficient	Standard Error 0.086
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 90	0.008 correlation coefficient	Standard Error 0.053
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 90	0.0327 correlation coefficient	Standard Error 0.053
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 30	0.025 correlation coefficient	Standard Error 0.315
OnabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 30	0.015 correlation coefficient	Standard Error 0.066
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 90	-0.012 correlation coefficient	Standard Error 0.039
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 3	0.046 correlation coefficient	Standard Error 0.047
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 90	-0.042 correlation coefficient	Standard Error 0.53
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 3	-0.013 correlation coefficient	Standard Error 0.052
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 180	-0.010 correlation coefficient	Standard Error 0.044
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 30	0.075 correlation coefficient	Standard Error 0.066
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 30	-0.018 correlation coefficient	Standard Error 0.061
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 180	-0.065 correlation coefficient	Standard Error 0.064
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 180	0.015 correlation coefficient	Standard Error 0.069
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 30	0.009 correlation coefficient	Standard Error 0.045
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 3	-0.010 correlation coefficient	Standard Error 83
AbobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 90	0.030 correlation coefficient	Standard Error 0.04
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 30	0.048 correlation coefficient	Standard Error 0.047
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 3	0.049 correlation coefficient	Standard Error 0.661
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 90	-0.015 correlation coefficient	Standard Error 0.046
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 30	-0.338 correlation coefficient	Standard Error 0.055
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 90	0.021 correlation coefficient	Standard Error 0.053
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 180	-0.071 correlation coefficient	Standard Error 0.0501
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 3	0.033 correlation coefficient	Standard Error 0.083
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 30	-0.002 correlation coefficient	Standard Error 0.07
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 90	0.015 correlation coefficient	Standard Error 0.069
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 180	-0.031 correlation coefficient	Standard Error 0.066
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 3	0.064 correlation coefficient	Standard Error 0.043
IncobotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 180	-0.133 correlation coefficient	Standard Error 0.041
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 30	-0.028 correlation coefficient	Standard Error 0.041
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 180	0.034 correlation coefficient	Standard Error 0.043
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 3	-0.038 correlation coefficient	Standard Error 0.041
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 3	-0.059 correlation coefficient	Standard Error 0.051
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 180	-0.014 correlation coefficient	Standard Error 0.09
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 90	-0.039 correlation coefficient	Standard Error 0.045
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 30	0.027 correlation coefficient	Standard Error 0.026
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 30	-0.0877 correlation coefficient	Standard Error 0.046
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines between Eyebrows Day 90	0.009 correlation coefficient	Standard Error 0.028
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Appraisal of Lines: Forehead Day 3	-0.095 correlation coefficient	Standard Error 0.045
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 180	0.111 correlation coefficient	Standard Error 0.063
PrabotulinumtoxinA	Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime	Satisfaction with Forehead Day 90	0.015 correlation coefficient	Standard Error 0.069

p-value: 0.433Wilcoxon signed rank sum

p-value: 0.834Wilcoxon signed rank sum

p-value: 0.526Wilcoxon signed rank sum test

p-value: 0.13519Wilcoxon signed-rank sum test

p-value: 0.8556Wilcoxon signed-rank sum test

p-value: 0.46943Wilcoxon signed-rank test

p-value: 0.0449Wilcoxon signed-rank sum test

p-value: 0.504Wilcoxon signed-rank sum test

p-value: 0.772193Wilcoxon signed-rank sum test

p-value: 0.5414Wilcoxon signed-rank sum test

p-value: 0.07Wilcoxon signed-rank sum test

p-value: 0.546Wilcoxon signed rank sum test

p-value: 0.756Wilcoxon signed rank sum test

p-value: 0.7Wilcoxon signed rank sum test

p-value: 0.397Wilcoxon signed rank sum

p-value: 0.093Wilcoxon signed rank sum

p-value: 0.323Wilcoxon signed rank sum

p-value: 0.182Wilcoxon signed rank sum

p-value: 0.88Wilcoxon signed rank sum

p-value: 0.496Wilcoxon signed rank sum

p-value: 0.905Wilcoxon signed rank sum

p-value: 0.692Wilcoxon signed rank sum

p-value: 0.262Wilcoxon signed rank sum

p-value: 0.828Wilcoxon signed rank sum

p-value: 0.268Wilcoxon signed rank sum test

p-value: 0.975Wilcoxon signed rank sum

p-value: 0.499Wilcoxon signed rank sum

p-value: 0.75Wilcoxon signed rank sum

p-value: 0.816Wilcoxon singed rank sum

p-value: 0.65wilcoxon signed rank sum

p-value: 0.095wilcoxon rank sum test

p-value: 0.618Wilcoxon signed rank sum

p-value: 0.34wilcoxon signed rank sum

p-value: 0.15Wilcoxon signed rank sum

p-value: 0.361Wilcoxon signed rank sum test

p-value: 0.428wilcoxon signed rank sum

p-value: 0.834Wilcoxon signed rank sum

p-value: 0.318wilcoxon signed rank sum

p-value: 0.311wilcoxon signed rank sum

p-value: 0.885Wilcoxon signed rank sum

p-value: 0.457Wilcoxon signed rank sum

p-value: 0.745Wilcoxon signed rank sum

p-value: 0.757wilcoxon signed rank sum

p-value: 0.562wilcoxon signed rank sum

p-value: 0.828wilcoxon signed rank sum

p-value: 0.005wilcoxon signed rank sum

p-value: 0.437wilcoxon signed rank sum

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026

Evaluation of Four Injectable Neuromodulators in the Glabella Area Glabella Area

Conditions

Keywords

Brief summary

Detailed description

Related papers

Interventions

Sponsors

Study design

Masking description

Intervention model description

Eligibility

Inclusion criteria

Exclusion criteria

Design outcomes

Primary

Secondary

Countries

Participant flow

Participants by arm

Withdrawals & dropouts

Baseline characteristics

Adverse events

Outcome results

the Change in Dynamic Strain in the Glabella Area After Injection Over Time

Correlation Patient Reported Satisfaction (FACE-Q) to the Degree of Dynamic Strain Overtime